Danaher Life Sciences and Agilent Technology joined existing backers Merck Group and Illumina for a $50m series B extension that increased the round’s total to nearly $89m.
France-based synthetic DNA producer DNA Script grew its series B round to $88.5m today following a $50m extension backed by laboratory equipment producer Agilent Technologies.
Danaher Life Sciences, a subsidiary of technology group Danaher, also contributed, as did M Ventures, the corporate venturing arm of pharmaceutical firm Merck Group, and Illumina Ventures, the investment division of gene sequencing technology producer Illumina.
The round was led by investment firm Casdin Capital. French state-owned investment bank Bpifrance contributed through its Large Venture…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
